期刊
WORLD JOURNAL OF CLINICAL CASES
卷 8, 期 1, 页码 97-102出版社
BAISHIDENG PUBLISHING GROUP INC
DOI: 10.12998/wjcc.v8.i1.97
关键词
Pembrolizumab; Pulmonary sarcomatoid carcinoma; Programmed death-ligand 1; Platinum-based chemotherapy; Non-small-cell lung cancer; Overall survival; Case report
BACKGROUND Few studies have addressed the efficacy of pembrolizumab in pulmonary sarcomatoid carcinoma (PSC), a rare, previously rapidly fatal subtype of non-small-cell lung cancer. CASE SUMMARY We report the case of a 69-year-old man presented with respiratory distress caused by a large left upper lung lobe mass diagnosed as PSC with programmed death-ligand 1 expressed on more than 50 percent of tumor cells. The patient was started on pembrolizumab and, after 5 cycles, there was a more than 80 percent decrease in the size of the tumor mass. Further decrease was seen at the end of 10 cycles. The patient has been tolerating pembrolizumab well, with no limiting side-effects. Fourteen months after first coming into the hospital, he remains asymptomatic. CONCLUSION Pembrolizumab appears as a viable emerging treatment for PSC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据